340B Better Together? PhRMA Partners With Community Health Centers On Legislative Reforms
Executive Summary
PhRMA's collaboration with the provider group may help alleviate concerns that legislators' pursuit of pharma-backed 340B reforms would pit lawmakers against hospitals that serve as a safety net for vulnerable patients.
You may also be interested in...
340B Program Spending Continues To Swell In 2022, Topping $53bn
Stakeholders differ on whether the rapid growth in spending is to be expected, given the realities in health care and specialty drug costs, or that the data underscores the need for oversight and reform of the 340B program.
340B Discounts Linked To Lower Hospital Costs For COPD When Savings Pass Directly To Patients
Research is published as the US Congress gears up to explore reforms of the 340B program. The findings align with pharma’s push to ‘share the savings’ but are not currently typical in the program, the Pharmaceutical Research and Manufacturers of America maintains.
Medicare Needs ‘Robust’ Claims Oversight So Inflation Rebates Won’t Duplicate 340B Discounts
PhRMA urges CMS to take a more proactive approach to monitoring 340B claims than previously proposed. Meanwhile, hospitals object to the claims modifier requirement.